10-K: NAII Reports FY25 Loss Amid Sales Growth, Credit Covenant Breach

Natural Alternatives International, Inc. reported a net loss of $13.575 million for fiscal year 2025 despite a 14% increase in net sales, driven by increased operational costs, a litigation settlement, and a significant deferred tax asset valuation allowance.

Summary

• Consolidated net sales increased 14% to $129.860 million in fiscal year 2025, up from $113.796 million in fiscal year 2024.
• Private-label contract manufacturing sales rose 16% to $121.779 million in fiscal year 2025, compared to $105.358 million in fiscal year 2024.
• Patent and trademark licensing revenue decreased 4% to $8.081 million in fiscal year 2025, from $8.438 million in fiscal year 2024.
• Gross profit increased 35% to $9.289 million in fiscal year 2025, up from $6.865 million in fiscal year 2024, with the gross profit margin improving from 6% to 7%.
• Net loss widened significantly to $13.575 million in fiscal year 2025, compared to a net loss of $7.217 million in fiscal year 2024.
• Loss from operations increased slightly to $8.660 million in fiscal year 2025, from $8.534 million in fiscal year 2024.
• Other selling, general and administrative expenses increased 7% to $16.549 million in fiscal year 2025.
• A $1.4 million expense was accrued in fiscal year 2025 for a litigation settlement and related legal costs associated with a PAGA claim.
• A $4.8 million valuation allowance was recognized against net domestic deferred income tax assets in fiscal year 2025.
• Cash and cash equivalents increased to $12.325 million at June 30, 2025, from $11.981 million at June 30, 2024.
• The company was not in compliance with the minimum net income and fixed charge coverage ratio covenants of its credit agreement for the quarter ending June 30, 2025, but received a prospective waiver.
• Anticipates non-compliance with modified credit agreement covenants in the first half of fiscal year 2026.
• Introduced TriBsyn, a new patent-pending beta-alanine product available as a raw material powder, designed to increase bioavailability and eliminate paresthesia.
• Customer concentration remains high, with three largest customers accounting for approximately 59% of consolidated net sales in fiscal year 2025 (down from 67.8% in fiscal year 2024).
• One supplier represented 18% of total raw material purchases in fiscal year 2025 (down from 23% in fiscal year 2024), and all beta-alanine is purchased from a single manufacturer in Japan.

Sentiment

Score: 3

Explanation: The company reported a significantly widened net loss for FY2025, driven by operational costs, a large tax valuation allowance, and a litigation settlement. Despite sales growth and new product launches, these financial challenges, coupled with anticipated credit covenant non-compliance and high customer/supplier concentration, indicate substantial near-term headwinds and financial instability.

Positives

• Consolidated net sales increased 14% year-over-year to $129.860 million, demonstrating growth in demand for products.
• Private-label contract manufacturing sales increased 16%, indicating strength in core business activities and new customer acquisitions.
• Gross profit margin improved from 6% to 7% in fiscal year 2025, suggesting better pricing or cost management in manufacturing.
• Successfully launched TriBsyn, a new patent-pending beta-alanine product with improved bioavailability and no paresthesia, opening new market segments like Wellness and Healthy Aging.
• Reopened the Carlsbad powder processing facility in May 2024 due to new customer orders, indicating a recovery in demand from a major customer.
• Received a prospective waiver for credit agreement covenant violations for the fourth quarter of fiscal year 2025, avoiding immediate default consequences.
• Cash and cash equivalents increased to $12.325 million, providing some liquidity.
• Successfully collected $2.9 million in Employee Retention Tax Credit refunds for the first and second quarters of calendar year 2021.

Negatives

• Net loss significantly widened to $13.575 million in fiscal year 2025, compared to $7.217 million in fiscal year 2024, indicating deteriorating profitability.
• Loss from operations increased slightly to $8.660 million, reflecting ongoing operational challenges.
• Patent and trademark licensing revenue, a higher-margin segment, decreased 4% to $8.081 million.
• Accrued a $1.4 million expense for a litigation settlement and related legal fees in fiscal year 2025, impacting financial results.
• Recognized a $4.8 million valuation allowance against net domestic deferred income tax assets, reflecting uncertainty about future taxable income in the U.S.
• Experienced unfavorable foreign currency exchange volatility and increased interest expense, contributing to a $1.2 million increase in other expense, net.
• Anticipates non-compliance with modified credit agreement covenants in the first half of fiscal year 2026, indicating continued financial instability and potential for further credit agreement revisions.
• High customer concentration, with three largest customers accounting for 59% of consolidated net sales, poses a significant risk if any of these relationships deteriorate.
• Reliance on a single supplier for all beta-alanine creates supply chain vulnerability.
• Continued upward pricing pressures for raw materials, packaging, labor, and transportation costs are expected through fiscal year 2026, potentially impacting future margins.
• The Carlsbad facility was temporarily closed in October 2023 due to excess customer inventory, highlighting demand volatility.

Risks

• A significant or prolonged economic downturn could materially adversely affect revenues and profit margins by lowering consumer demand for products.
• Global economic instability, including supply chain issues, inflation, fuel and energy costs, and geopolitical tensions (Ukraine-Russia, Israel-Hamas conflicts), may affect raw material availability and pricing.
• The highly competitive nutritional supplement industry, characterized by low entry barriers, could lead to price reductions, reduced profit margins, or loss of market share.
• Adverse publicity or negative public perception about the company, its products, or the industry could negatively affect sales and revenues.
• Inability to attract and retain qualified management and key manufacturing personnel could adversely affect business strategies and objectives.
• Manufacturing and third-party fulfillment activities are subject to risks such as power failures, natural disasters, cybersecurity vulnerabilities, equipment breakdowns, and compliance with governmental requirements.
• Expansion into additional markets outside the U.S. or increased international sales expose the business to political, economic, regulatory, and other risks, including import/export controls, customs duties, currency exchange rates, and instability.
• Failure of limited raw material suppliers, particularly the single source for beta-alanine, to provide quality materials in sufficient quantities, at favorable prices, and in a timely fashion could adversely affect operations.
• High customer concentration (59% from three largest customers in FY2025) makes the company vulnerable to the loss of a major customer or significant changes in their business.
• Inability to diversify sales and develop new product sales from both current and new customer relationships could adversely affect operating results.
• The ability to maintain or grow beta-alanine sales and license revenue is contingent on defending patents and commercializing new product forms (SR CarnoSyn, TriBsyn).
• Extensive government regulation (FDA, FTC, international agencies) could limit or prevent product sales, increase costs, and result in enforcement actions for non-compliance.
• Possible new tariffs on imported goods from China and elsewhere could adversely affect business operations, raw material costs, and customer competitiveness.
• Exposure to product liability claims or other litigation, which may be costly and not fully covered by insurance, could materially adversely affect operations.
• Incurring significant costs in creating and defending intellectual property, or inadvertently infringing on the intellectual property rights of others, could have a material adverse effect.
• Certain provisions in the Certificate of Incorporation, Bylaws, and Delaware law may discourage unsolicited proposals to acquire the business.
• Significant insider ownership (21% by officers and directors, 15% by CEO Mark LeDoux) could influence corporate transactions and limit the influence of other stockholders.
• Pursuing acquisitions of other companies, if not successful, could adversely affect business, financial condition, and results of operations due to integration difficulties, diversion of management, and other risks.
• Operating results are expected to vary, and fluctuations may adversely affect the share price of common stock.
• Stock price could fluctuate significantly due to broad market conditions, financial results, low trading volumes, future offerings, industry conditions, regulatory action, adverse publicity, or manipulative trading practices.
• Inability to raise additional capital or obtain additional financing if needed could negatively affect the ability to implement business strategies and meet goals.
• Cybersecurity threats to information systems could have a material negative impact upon business, results of operations, or financial condition.

Future Outlook

The company anticipates experiencing a net loss in the first half of fiscal year 2026, followed by net income in the second half, resulting in net income for the full fiscal year 2026. Management expects upward pricing pressures for raw materials, packaging components, and other costs to continue throughout fiscal year 2026 due to limited supplies, higher labor and transportation costs, and tariffs. The company is currently negotiating a potential revision to its credit agreement due to anticipated non-compliance with modified covenants in the first half of fiscal year 2026.

Management Comments

• Our vision is to enrich the world through the best of nutrition.
• We believe SR CarnoSyn is a superior delivery system of CarnoSyn beta-alanine based on its sustained release profile that allows for increased daily dosing and improved muscle retention of carnosine.
• With the introduction of our recent product called TriBsyn, and its patent-pending formulation, we believe we now have a product that will allow us to better penetrate the Wellness and Healthy Aging channel.
• The elimination of paresthesia while maintaining efficacy of dosage creates a new opportunity to reach segments of the market that to-date have been untapped, including older adults, vegetarians, and vegans.
• We are also working on several other innovations that could lead to new patentable products for CarnoSyn Brands in the future.
• Overall, we believe there is an opportunity to enhance consumer confidence in the quality of our customers' nutritional supplements and their adherence to label claims through education provided by direct sales and direct-to-consumer marketing programs.
• We believe our GMP and TGA certified manufacturing operations, science-based product formulations, peer-reviewed clinical studies and regulatory expertise collectively provide us with a sustainable competitive advantage and provide our customers with a high degree of confidence in the products we manufacture.
• We currently anticipate we will experience a net loss in the first half of fiscal 2026, net income in the second half of fiscal 2026, and net income for the full fiscal 2026 year.

Industry Context

The nutritional supplement industry is highly fragmented and competitive, characterized by relatively low entry barriers. The company emphasizes its comprehensive solutions, certified manufacturing operations, commitment to quality and safety, and research and development activities as key competitive advantages. The direct sales marketing channel is viewed as a highly effective method for marketing high-quality nutritional supplements due to its ability to educate consumers. The company is targeting growth opportunities in the Wellness and Healthy Aging markets with new beta-alanine product offerings like SR CarnoSyn and TriBsyn. The industry continues to face challenges from global supply chain issues, inflationary pressures, and geopolitical conflicts, impacting raw material availability and pricing.

Comparison to Industry Standards

• The company's extensive certifications (TGA, NSF, NSF for Sport, Health Canada, Organic Processor, SSCI, Swissmedic, FSSC 22000) demonstrate a strong commitment to quality and safety, positioning it favorably against competitors who may not adhere to such rigorous standards.
• The introduction of TriBsyn, a beta-alanine product designed to eliminate paresthesia and increase bioavailability, represents an innovative approach to product development, potentially allowing the company to tap into underserved market segments like older adults, vegetarians, and vegans, which may differentiate it from standard offerings.
• The gross profit margin improvement from 6% to 7% in fiscal year 2025, while positive, remains relatively low for a specialized manufacturer, suggesting that the company may face significant cost pressures or operate in a highly competitive pricing environment compared to industry benchmarks.
• The high customer concentration, with three largest customers accounting for 59% of consolidated net sales, and reliance on a single supplier for beta-alanine, indicates a higher risk profile compared to industry best practices for diversification, which typically aim to reduce dependence on a few key relationships.
• The company's ongoing investment in research and development for new science-based products and clinical studies aligns with industry trends emphasizing evidence-backed nutritional supplements, providing a competitive edge over less scientifically driven manufacturers.

Corporate Governance

Legal Proceedings

• In December 2023, the company was sued by three former employees in two separate, substantially identical putative class action and Private Attorney General Act ('PAGA') lawsuits, seeking awards for similarly situated employees going back ten years or more.
• On July 3, 2025, a tentative settlement agreement was reached in these lawsuits, whereby the company agreed to contribute a maximum of $1.25 million.
• The company accrued the maximum settlement amount of $1.25 million and estimated related legal fees of approximately $0.15 million in its results of operations as of June 30, 2025.
• The process of obtaining court approval for the settlement is estimated to take approximately one year.
• As of September 23, 2025, with the exception of these two matters, neither NAI nor NAIE were a party to any material pending legal proceeding.

Stakeholder Impact

• Shareholders: Negative impact due to a significant net loss, increased operational costs, and potential stock price volatility. There is also a risk of dilution if future equity capital raises become necessary.
• Employees: Positive impact from the enhanced 401(k) plan matching (50% of the first 6% of compensation) effective January 1, 2025. However, the litigation settlement with former employees could indicate past employee relations issues.
• Customers: Potential impact from ongoing supply chain challenges, raw material pricing pressures, and tariffs, which may be passed through. Conversely, customers benefit from new product offerings like TriBsyn and the company's comprehensive strategic partnering services and certified manufacturing.
• Suppliers: Continued demand for raw materials, but also pressure to mitigate cost increases. The company's reliance on a single supplier for beta-alanine creates a concentrated risk for both the company and that supplier.
• Creditors (Wells Fargo Bank): The company's non-compliance with credit agreement covenants and the need for renegotiation indicate increased financial risk for its lender.

Next Steps

• Continue efforts to diversify sales by developing relationships with additional quality-oriented private-label contract manufacturing customers.
• Expand the commercialization of the beta-alanine patent estate through raw material sales and developing sales distribution channels in Sports Nutrition, Wellness, Healthy Aging, and Medical foods for SR CarnoSyn and TriBsyn product lines.
• Improve operational efficiencies and manage costs and business risks to improve profitability.
• Continue sales and marketing activities to consumers, customers, potential customers, and brand owners to promote CarnoSyn, SR CarnoSyn, and TriBsyn beta-alanine products.
• Negotiate a potential revision to the credit agreement with Wells Fargo Bank due to anticipated covenant non-compliance in the first half of fiscal year 2026.
• Continue to incur intellectual property litigation and patent compliance expenses (expected between $0.1 million and $0.3 million during fiscal year 2026).
• Monitor and mitigate the impacts of geopolitical conflicts and tariffs on raw material sourcing and costs.
• Complete the court approval process for the $1.25 million litigation settlement, which is estimated to take approximately one year.
• Evaluate the impact of ASU 2024-03 on financial statements for adoption in the annual financial statements for the year ending June 30, 2028.
• Adopt ASU 2023-09 in annual financial statements for the year ending June 30, 2026.

Key Dates

Recommendation

The company reported a significantly widened net loss for fiscal year 2025, driven by operational inefficiencies, a substantial tax valuation allowance, and a litigation settlement. Despite a 14% increase in sales, profitability remains a major concern. The company is also in breach of its credit agreement covenants and anticipates further non-compliance, necessitating renegotiation with its lender, which introduces significant financial uncertainty. High customer and single-source supplier concentration, coupled with ongoing inflationary pressures and geopolitical risks, further exacerbate the challenging outlook. While new product introductions like TriBsyn offer long-term potential, the immediate financial health and operational risks suggest a negative investment outlook, warranting a 'sell' recommendation.

Keywords

Nutritional Supplements, Contract Manufacturing, Beta-Alanine, CarnoSyn, SR CarnoSyn, TriBsyn, Dietary Supplements, Health Products, SEC Filing, 10-K, Financial Results, Supply Chain, Intellectual Property, Corporate Governance, NAII, Natural Alternatives International